MDACC Study No:2013-0090 ( NCT No: NCT01880567)
Title:A Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients with Newly Diagnosed MCL
Principal Investigator:Michael Wang
Treatment Agent:Ibrutinib; Rituximab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if a combination of
ibrutinib and rituximab can help control MCL in patients with relapsed or
refractory disease or in patients over 65 who have newly diagnosed MCL. The
safety of this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Ibrutinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Janssen Pharmaceuticals
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults